Effects of YM905, a novel muscarinic M3-receptor antagonist, on experimental models of bowel dysfunction in vivo.

@article{Kobayashi2001EffectsOY,
  title={Effects of YM905, a novel muscarinic M3-receptor antagonist, on experimental models of bowel dysfunction in vivo.},
  author={Seiji Kobayashi and Katsumi Ikeda and Mamoru Suzuki and Tomoko Yamada and K. Miyata},
  journal={Japanese journal of pharmacology},
  year={2001},
  volume={86 3},
  pages={281-8}
}
We investigated the effects of YM905 [(+)-(1S,3'R)-quinuclidin-3'-yl 1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate monosuccinate], a new orally active muscarinic M3-receptor antagonist, on bowel dysfunction in vivo using experimental models that reproduce the symptoms present in irritable bowel syndrome (IBS). YM905 potently inhibited restraint stress-induced fecal pellet output in fed rats (ED50: 4.0 mg/kg) and diarrhea in fasted rats (ED50: 1.7 mg/kg), with similar potencies to the… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 32 references

YM905, a novel antimuscarinic agent displays tissue preference for the urinary bladder M3 receptor

  • K Ikeda, M Suzuki, +4 authors K Honda
  • FASEB J 13,
  • 1999

Similar Papers

Loading similar papers…